Rat?....sell your shares please, love to buy more!
MRNA ip is broad and holds much potential in the future of nucleic acid therapies.
One more thought...since SMARTICLES is so widely used in clinical trials I suspect at least a $4 buyout if positive trials result. Don't you think one big pharma will pay huge bucks to exclusively own this ip??
Michael French, president and CEO of Marina Biotech. "In addition, I believe it is also the most widely used delivery technology in human clinical studies for the development of nucleic acid therapeutics
BOTHELL, WA and SAN DIEGO, CA--(Marketwired - Dec 18, 2014) - Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, and MiNA Therapeutics Limited, the pioneer in RNA activation therapeutics, announced today that they have entered into a license agreement regarding the development and commercialization of small activating RNA (saRNA) based therapeutics utilizing MiNA's proprietary oligonucleotides and Marina's novel SMARTICLES nucleic acid delivery technology. MiNA will have full responsibility for the development and
commercialization of any products arising under the Agreement and Marina Biotech will support pre-clinical and process development efforts. Under terms of the Agreement, Marina Biotech could receive up to $50 million in total upfront, clinical and commercialization milestone payments, as well as royalties on sales, based on the successful outcome of the collaboration. Further terms of the Agreement were not disclosed.
"MiNA is focused on rapidly translating the benefits of saRNA therapeutics into the clinic," said Robert Habib, CEO of MiNA Therapeutics. "SMARTICLES have demonstrated highly efficient delivery of saRNAs to the liver and solid tumors along with a strong clinical track record and robust manufacturing. The formulation of saRNAs with SMARTICLES both accelerates and de-risks the development of MiNA's technology platform."
"SMARTICLES is the most widely licensed delivery technology in the nucleic acid therapeutics sector now licensed to deliver single-stranded DNA oligonucleotides, double-stranded microRNA mimics and both single and double-stranded small activating RNA," stated J. Michael French, president and CEO of Marina Biotech. "In addition, I believe it is also the most widely used delivery technology in human clinical studies for the development of nucleic acid therapeutics. We are excited to be partnered with the pioneer in RNA activation therapeutics and...
Looking forward to next years results, btw I still think BTX and MRNA will collaborate on nano-peptide tumor targeting together sometime in 2015.
When positive Smarticle results come in big pharma will be fighting to buy us up. The key here is 'delivery', currently very few known ways to deliver RNAI/cells/drugs within the body......and MRNA has patented two
GE Healthcare and Cellular Dynamics International Agree to Sublicense for Cellular Assay Patents
Chalfont St. Giles, UK and MADISON, WIS, USA – 18 December 2012 – GE Healthcare Life Sciences, a business unit of GE Healthcare (NYSE: GE) and Cellular Dynamics International (CDI), a leading commercial producer of human induced pluripotent stem (iPS) cell lines and tissue cells, announced today that GE Healthcare has licensed CDI to develop, manufacture and sell cellular assays and models derived from induced pluripotent stem (iPS) cells for use in drug discovery and toxicity screening. The agreement follows the recent announcement that GE Healthcare has expanded its license with Geron to obtain exclusive global rights to Geron’s intellectual property and know-how for the development and sale of cellular assays derived from iPS cells. Financial terms were not disclosed.
News from 2012, GE strikes deal with our top competitor Cellular Dynamics for drug testing/discovery using ips cells. Seems to me yesterday's BTX/GE deal tops this in that BTX acquires rights to use The GE/Geron ip left out in the BTX acquisition of Geron. And again GE goes with BTX and the hESC Gold Standard.
Actually Dr West said something about not having enough time to include but we all know it's top secret and they want to keep it under wraps. Good news is that it will make a soft launch within a couple of weeks.
PanC-DX(cancer diagnostic products) peer review papers were submitted and there will be presentations this Spring at the annual cancer screening conference. Block buster products on the market possibly within one year!
Still under the radar. Cramer and CNBC guys will be talking about us next year.......after they buy up shares.
BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OncoCyte Corporation today announced that OncoCyte has completed enrollment in the initial clinical study of its urine-based bladder cancer diagnostic test. The study, which involved 100 patients, was conducted in collaboration with investigators in the Department of Pathology, Division of Cytopathology, at a leading medical institution with an international reputation for excellence and discovery. Initial results of the study have been submitted for presentation at a large upcoming cancer society meeting; eventual publication of the final results in a peer-reviewed clinical journal is also anticipated.
The goal of this clinical study was to assess the performance of OncoCyte’s proprietary diagnostic technology in detecting the most common type of bladder cancer; namely, urothelial carcinoma (UC) (previously designated transitional cell carcinoma). Study investigators collected urine samples from patients undergoing urine cytology for the diagnosis of either primary or recurrent bladder cancer. Patient urine samples were assessed microscopically for the presence of cancer cells using the current standard-of-care method of cytopathology; in parallel, OncoCyte scientists analyzed the remaining portion of the urine samples for gene expression, including expression of OncoCyte’s proprietary PanC-Dx™ markers. In some cases, the quality of the residual urine sample provided to OncoCyte did not allow for a valid analysis; in these cases additional replacement samples will be provided. A statistical analysis was performed and a panel of markers that discriminates UC from non-cancerous conditions was identified. The ability of the markers tested in the studies to determine the absence, presence, or progression of UC in patients will determine the specific nature of the bladder cancer test to be developed and the regulatory approval pathway that OncoCyte will pursue.
“There is a large and growing need for more sensitive, cost